Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01727869 · ClinicalTrials.gov registry record · Phase 1

Study of REGN1400 Alone and in Combination With Erlotinib or Cetuximab in Patients With Certain Types of Cancer

A Phase 1 study of Cancer, sponsored by Regeneron Pharmaceuticals.

Completed
Registry status
Phase 1
Development phase
56
Enrollment target
6
Study locations

NCT01727869 is a Phase 1 study of Cancer that has completed, run by Regeneron Pharmaceuticals. The registered enrollment target is 56 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (98% lower). The trial reports 6 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01727869, a Phase 1 study of Cancer, has completed, sponsored by Regeneron Pharmaceuticals.

COMPLETED
Registry status
Phase 1
Development phase
56 participants
Enrollment target
6
Study locations

Study Summary

This is an open-label, multicenter, ascending multiple dose study of REGN1400 alone and in combination with erlotinib or cetuximab administered to patients with certain types of cancer.

Conditions Studied

Cancer

Interventions

  • DRUG Cetuximab
  • DRUG Erlotinib
  • DRUG REGN1400

Study Locations (6)

New York

  • - Buffalo
  • - New York

California

  • - Santa Monica

Georgia

  • - Atlanta

Michigan

  • - Detroit

Texas

  • - San Antonio

Trial Details

FieldValue
Enrollment Target 56 participants
Start Date 2012-10
Est. Completion 2015-01
Phase Phase 1

Sponsor

Regeneron Pharmaceuticals

280 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01727869

The ClinicalTrials.gov registry entry for NCT01727869 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (98% lower). The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Cancer appearing as the primary indexed condition, and to 3 interventions - of which Cetuximab is the first listed.

NCT01727869 reports 6 study locations spanning 5 distinct geographic areas - top geographies include New York, California, Georgia.

Frequently Asked Questions

What is clinical trial NCT01727869 about?

NCT01727869 is a clinical study titled "Study of REGN1400 Alone and in Combination With Erlotinib or Cetuximab in Patients With Certain Types of Cancer". This is an open-label, multicenter, ascending multiple dose study of REGN1400 alone and in combination with erlotinib or cetuximab administered to patients with certain types of cancer.

What is the current status of trial NCT01727869?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2012-10. Estimated completion is 2015-01.

What conditions does trial NCT01727869 study?

This clinical trial studies the following conditions: Cancer.

What interventions are being tested in trial NCT01727869?

The interventions under investigation include: Cetuximab (DRUG), Erlotinib (DRUG), REGN1400 (DRUG).

Who is sponsoring clinical trial NCT01727869?

This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01727869 being conducted?

This trial has 6 study locations across California, Georgia, Michigan, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Cancer

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.